SLC5A2 and cardiomyopathy: The EMPULSE trial (13) and the SOLOIST-WHF (10) assessed the impact of SGLT2 inhibitors on patient symptoms, physical activity limitation, and quality of life by administering the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS).